SEC Tracker
Get the app

GoodRx Holdings GDRX

GoodRx Holdings restates revenue for 2026 periods

Item 4.02 Restates past financials

Form
8-K
Filed
Importance
Major
  1. Pharma Direct revenue understated by $7.5M for March 2026
  2. Total revenue increased by $7.5M for March 2026
  3. Operating income rose by $5.3M for March 2026
  4. Net income increased by $3.79M for March 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when GoodRx Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. This led to an understatement of Pharma Direct revenue and total revenue.
  2. The company has not identified any impact on financial statements prior to fiscal year 2026.

2 of 5 claims matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, GoodRx reported revenue of $200.4 million, net income of $8.5 million, and an operating margin of 11.8%.
  • The company also noted a 1.3% decrease in revenue compared to the same period a year earlier.
  • These figures are from the 10-Q filing for the quarter ended June 30, 2026.

From the filing

Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related A

Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim

Review

On October 27, 2026, the Audit and Risk Committee of the Board of Directors (the "Board") of GoodRx Holdings, Inc. (the "Company"), after discussion with management of the Company and the Company's independent registered public accounting firm, KPMG LLP ("KPMG"), concluded that the Company's condensed consolidated financial statements for the fiscal quarter and year-to-date periods ended March 31, 2026 and June 30, 2026 (collectively, the "Affected Periods") should no longer be relied upon due to the understatement of Pharma Direct revenue. Similarly, any previously issued or filed reports, press releases, earnings releases, and investor presentations or other communications describing the Company's condensed consolidated financial statements and other related financial information for the Affected Periods should no longer be relied upon.

In connection with an ongoing Audit and Risk Committee review of the Company's revenue recognition for certain transactions related to Pharma Direct revenue, the Company determined that a portion of revenue was not recognized during each Affected Period that should have been recognized in each such period in accordance with Accounting

Standards Codification 606. This error resulted in an understatement of Pharma Direct revenue and total revenue in each Affected Period1. The Company has not identified any impact to previously issued financial statements for periods prior to fiscal year 20262.

The Company expects the principal effects on its previously reported results for the Affected Periods to be as follows:

(in thousands, except for per share amounts)

Three months ended March 31, 2026 Three months ended June 30, 2026 Six months ended June 30, 2026

As Reported

Restatement

Adjustments

As Restated

As Reported

Restatement

Adjustments

As Restated

As Reported

Restatement

Adjustments

As Restated

Pharma Direct revenue

$ 5

Similar companies

Companies of similar size in SIC 7374 and related industry codes: the same peer list as the financial tables.

  1. Appian APPN
  2. Bandwidth BAND public float $431M, Jun 30, 2025
  3. IBEX IBEX public float $431M, Dec 31, 2025
  4. Nextdoor Holdings NXDR public float $434M, Jun 30, 2025
  5. Veradigm MDRX public float $408M, Jun 30, 2025